M Borgs

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

D B Evans, M. Ellis, Baljit Singh, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.